Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

Blood (2019) 133 (21): 2291–2304.

https://doi.org/10.1182/blood-2018-10-882944

Published: 2019

Includes: Supplemental data

Journal Articles

Prophylaxis of Invasive Pulmonary Aspergillosis with Nebulized Lipid Complex Amphotericin B Is Feasible, Well Tolerated and Safe in Children with Acute Leukemia. Results of a Phase II Open Trial

Maria Trabazo, Albert Catala, Ruben Berrueco, Gabriela Corbalan, Anna Ruiz, Maria Poveda, Mireia Camos, Montserrat Torrebadell, Teresa Toll, Anna Alonso, Montserrat Mesegue, Joan Vinent, Maria Luisa Martin-Saenz, Cristina Llanos, Alicia Castaneda, Amadeu Gene, Teresa Juncosa, Jesus Estella, Susana Rives

Blood (2014) 124 (21): 1409.

https://doi.org/10.1182/blood.V124.21.1409.1409

Published: 2014

Journal Articles

FLT3 Is Involved In Ara-C Transport By Human Equilibrative Nucleoside Transporter (hENT1) In Pediatric Acute Leukemia

Albert Català, MarÇal Pastor-Anglada, Roberta Malatesta, Susana Rives, Montserrat Torrebadell, Teresa Toll, Ruben Berrueco, Jesús Estella, Mireia Camós, Paula Fernández-Calotti

Blood (2013) 122 (21): 3844.

https://doi.org/10.1182/blood.V122.21.3844.3844

Published: 2013

Journal Articles

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3 -ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

Blood (2013) 121 (14): 2734–2738.

https://doi.org/10.1182/blood-2012-06-431122

Published: 2013

Includes: Supplemental data

Journal Articles

The Distinctive MicroRNA Signature of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13)/MYST3-CREBBP Is Responsible for RET Overexpression and Is Regulated by Epigenetic Mechanisms

Marina Díaz-Beyá, MD, Alfons Navarro, PhD, Tania Díaz, PhD, Gerardo Ferrer, Rut Tejero, Mireia Camós, MD, PhD, Montserrat Torrebadell, MD, Marta Pratcorona, MD, Maria Rozman, MD, PhD, Mariano Monzó, MD, PhD, Jordi Esteve, MD, PhD

Blood (2011) 118 (21): 2434.

https://doi.org/10.1182/blood.V118.21.2434.2434

Published: 2011

Journal Articles

The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status

Marina Díaz-Beyá, María Rozman, Marta Pratcorona, Montserrat Torrebadell, Mireia Camós, Josep Ll. Aguilar, Jordi Esteve

Blood (2010) 116 (26): 6147–6148.

https://doi.org/10.1182/blood-2010-09-307314

Published: 2010

Journal Articles

A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement

Marina Díaz Beyá, MD, Alfons Navarro, PhD, Tania Díaz, Bernat Gel, Mireia Camós, MD, PhD, Marta Pratcorona, MD, Montserrat Torrebadell, MD, María Rozman, MD, PhD, Margherita Maffioli, MD, Mariano Monzó, MD, PhD, Jordi Esteve, MD, PhD

Blood (2010) 116 (21): 230.

https://doi.org/10.1182/blood.V116.21.230.230

Published: 2010

Journal Articles

T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.

Neus Villamor, Gonzalo Gutierrez, Joaquim Carreras, Eva Gine, Gabriela Ghita, Marta Aymerich, Montserrat Torrebadell, Antonio Martinez, Luis Colomo, Emili Montserrat, Elias Campo, Armando Lopez-Guillermo

Blood (2009) 114 (22): 1945.

https://doi.org/10.1182/blood.V114.22.1945.1945

Published: 2009

Journal Articles

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Marta Pratcorona, Montserrat Torrebadell, Neus Villamor, Maria Rozman, Mireia Camós, Ana Carrió, Dolors Costa, Marina Díaz Beyáa, Emili Montserrat, Jordi Esteve

Blood (2009) 114 (22): 2611.

https://doi.org/10.1182/blood.V114.22.2611.2611

Published: 2009

Journal Articles

Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics

Marta Pratcorona, Mireia Camós, Montserrat Torrebadell, Maria Rozman, Ana Carrió, Dolors Costa, Alexandra Valera, Elias Campo, Emili Montserrat, Jordi Esteve

Blood (2008) 112 (11): 2522.

https://doi.org/10.1182/blood.V112.11.2522.2522

Published: 2008

Journal Articles

Molecular Markers Predicting Clinical Outcome in Patients with Intermediate-Risk Acute Myeloid Leukemia Receiving Autologous Stem Cell Transplantation.

Jordi Esteve, MD, Susana Kalko, PhD, Montserrat Torrebadell, MD, Mireia Camos, MD, Pedro Jares, PhD, Maria Rozman, MD, Marta Pratcorona, MD, Salut Brunet, MD, Josep Nomdedeu, MD, Ana Carrio, PhD, Dolors Costa, PhD, Emili Montserrat, MD

Blood (2007) 110 (11): 604.

https://doi.org/10.1182/blood.V110.11.604.604

Published: 2007

Journal Articles

Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.

María Rozman, MD, Susana G. Kalko, PhD, Jordi Esteve, MD, Mireia Camós, MD, Josep-Lluís Aguilar, MD, Montserrat Torrebadell, MD, Dolors Costa, PhD, Ana Carrió, PhD, Pedro Jares, PhD, Emili Montserrat, MD, Elías Campo, MD

Blood (2006) 108 (11): 2244.

https://doi.org/10.1182/blood.V108.11.2244.2244

Published: 2006

NARROW

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

Prophylaxis of Invasive Pulmonary Aspergillosis with Nebulized Lipid Complex Amphotericin B Is Feasible, Well Tolerated and Safe in Children with Acute Leukemia. Results of a Phase II Open Trial

FLT3 Is Involved In Ara-C Transport By Human Equilibrative Nucleoside Transporter (hENT1) In Pediatric Acute Leukemia

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3 -ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

The Distinctive MicroRNA Signature of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13)/MYST3-CREBBP Is Responsible for RET Overexpression and Is Regulated by Epigenetic Mechanisms

The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status

A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement

T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics

Molecular Markers Predicting Clinical Outcome in Patients with Intermediate-Risk Acute Myeloid Leukemia Receiving Autologous Stem Cell Transplantation.

Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only